Praxis' Elsunersen Delivers Strong 77% Seizure Reduction in Key EMBRAVE Part A Trial
PRAX has more than doubled off its 52-week low of $26.7.
Summary
Praxis Precision Medicines announced highly positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A early-onset developmental and epileptic encephalopathy (DEE). The drug achieved a significant 77% placebo-adjusted seizure reduction from baseline, with 71% of patients experiencing over 50% reduction. Crucially, 100% of elsunersen-treated patients also showed improvements in sleep, motor function, and attention, with no drug-related serious adverse events reported.
This strong clinical data for elsunersen, a key pipeline asset, reinforces the company's R&D capabilities, following the recent FDA acceptance of an NDA for their relutrigine drug. These results are a major positive catalyst, indicating elsunersen's potential as a disease-modifying treatment for a severe neurological disorder, which could significantly enhance Praxis's long-term revenue prospects and valuation. Investors will now closely monitor the progress of the pivotal EMBRAVE3 study and subsequent regulatory milestones.
At the time of this announcement, PRAX was trading at $310.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $26.70 to $356.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.